Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for Macrophage Activation Syndrome in Still's Disease and SLE
2024-516153-52-00Phase 3Completed
- Sponsor
- Sobi
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of emapalumab in macrophage activation syndrome (MAS), systemic juvenile idiopathic arthritis (SJIA), adult-onset Still's disease (AOSD) and 1 more, sponsored by Sobi. Primary endpoint: Proportion of patients with complete response at Week 8. Started Sep 2024; status: completed.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)systemic juvenile idiopathic arthritis (SJIA)adult-onset Still's disease (AOSD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-516153-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516153-52-00.